What Are the Early Symptoms of PML in Tysabri Patients?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Occupational Risk

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wondered what early signs to watch for. Decades of pharmacovigilance have established a clear link between this medication and PML, particularly in patients with certain risk factors. This page outlines the clinical signals of PML, including symptom patterns and recommended monitoring protocols, to help you stay informed.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. This section summarizes the medical evidence linking Tysabri to PML, the clinical presentation of the disease, and considerations for affected patients, including legal aspects. Progressive multifocal leukoencephalopathy is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised and that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, balance disorder, cognitive impairment, memory impairment, and visual changes. These symptoms overlap with those of multiple sclerosis, making diagnosis challenging. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors that are known to increase the risk of PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration especially beyond 2 years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism, Timeline, and Post-Marketing Evidence

The mechanistic pathway involves Tysabri's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow reactivation of latent JCV in the brain, leading to PML. The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks, and these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has documented numerous adverse events associated with Tysabri, including fatigue (19150 reports), multiple sclerosis relapse (16691 reports), headache (9626 reports), gait disturbance (9422 reports), memory impairment (7895 reports), balance disorder (5621 reports), and cognitive disorder (3478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not all represent PML, they highlight the range of neurological symptoms that may be reported by patients.

Risk Warnings and Legal Considerations for Affected Patients

The adequacy of warnings regarding Tysabri and PML is a critical risk anchor. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML and that risk factors include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and healthcare providers were adequately informed about the magnitude and nature of the risk, particularly in the context of individual risk factors. For patients who develop PML after Tysabri treatment, attorney-related considerations may be relevant. Affected individuals may seek legal counsel to explore whether the manufacturer provided sufficient warnings about the risk of PML, whether the TOUCH program was properly implemented, and whether there were delays in diagnosis or treatment. The timeline between exposure and documented harm is important for legal claims, as PML can occur after varying durations of treatment, from months to years. Patients who experience PML may face severe disability or death, and legal action may seek compensation for medical expenses, lost income, and pain and suffering. In summary, Tysabri is associated with a known risk of PML, a severe brain infection that can lead to death or disability. The risk is influenced by anti-JCV antibody status, treatment duration, and prior immunosuppressant use. Clinical presentation of PML includes neurological deficits that may be mistaken for multiple sclerosis symptoms. The FDA has required boxed warnings and a restricted distribution program, but affected patients may still have legal recourse if they believe warnings were inadequate. Anyone considering Tysabri therapy should discuss the risks and benefits with their healthcare provider and be vigilant for symptoms of PML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it increase the risk of PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, by inhibiting lymphocyte migration into the central nervous system, which can allow reactivation of latent JCV. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What are the known risk factors for developing PML while on Tysabri?

Three factors increase PML risk: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What legal options are available for patients who developed PML after Tysabri treatment?

Affected patients may seek legal counsel to explore claims regarding inadequate warnings, improper implementation of the TOUCH program, or delays in diagnosis. Legal action may seek compensation for medical expenses, lost income, and pain and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.